A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs SCY 635 (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors SCYNEXIS
- 13 Nov 2012 Results were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), according to a SYNEXIS media release.
- 29 May 2012 Actual patient number is 11 according to ClinicalTrials.gov.
- 29 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History